Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Merryman, Reid W  [Clear All Filters]
Journal Article
Merryman RW, Rhoades J, Xiong K, Redd RA, Antel K, An HHwan, McDonough M, Guerrero L, Crnjac A, Sridhar S, et al. Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma. Hemasphere. 2024;8(4):e47.
Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, et al. Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma. Transplant Cell Ther. 2021.
Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2022.
Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSubramania, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, et al. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021.
Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, Lacasce AS, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122-126.
Merrill MH, Dahi PB, Redd RA, McDonough M, Bin Chen Y-, DeFilipp Z, Herrera AF, Fisher DC, Lacasce AS, Odejide OO, et al. A Phase 2 Study of pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell non-Hodgkin Lymphoma. Blood. 2023.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858-867.